Literature DB >> 27825667

Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.

Hazem E Ghoneim1, Anthony E Zamora2, Paul G Thomas2, Ben A Youngblood3.   

Abstract

Prolonged exposure of CD8+ T cells to their cognate antigen can result in exhaustion of effector functions enabling the persistence of infected or transformed cells. Recent advances in strategies to rejuvenate host effector function using Immune Checkpoint Blockade have resulted in tremendous success towards the treatment of several cancers. However, it is unclear if T cell rejuvenation results in long-lived antitumor functions. Emerging evidence suggests that T cell exhaustion may also represent a significant impediment in sustaining long-lived antitumor activity by chimeric antigen receptor T cells. Here, we discuss current findings regarding transcriptional regulation during T cell exhaustion and address the hypothesis that epigenetics may be a potential barrier to achieving the maximum benefit of T cell-based immunotherapies. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA methylation.; T cell exhaustion; chimeric antigen receptor T cells; epigenetics; histone modification; immune checkpoint blockade

Mesh:

Substances:

Year:  2016        PMID: 27825667      PMCID: PMC5135632          DOI: 10.1016/j.molmed.2016.10.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  79 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Rapid demethylation of the IFN-gamma gene occurs in memory but not naive CD8 T cells.

Authors:  Ellen N Kersh; David R Fitzpatrick; Kaja Murali-Krishna; John Shires; Samuel H Speck; Jeremy M Boss; Rafi Ahmed
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

Review 3.  Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs.

Authors:  Pranay Dogra; Hazem E Ghoneim; Hossam A Abdelsamed; Ben Youngblood
Journal:  Eur J Immunol       Date:  2016-07       Impact factor: 5.532

4.  Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Christopher D Scott; Anthony J Leonardi; Tori N Yamamoto; Anthony C Cruz; Claudia Ouyang; Madhu Ramaswamy; Rahul Roychoudhuri; Yun Ji; Robert L Eil; Madhusudhanan Sukumar; Joseph G Crompton; Douglas C Palmer; Zachary A Borman; David Clever; Stacy K Thomas; Shashankkumar Patel; Zhiya Yu; Pawel Muranski; Hui Liu; Ena Wang; Francesco M Marincola; Alena Gros; Luca Gattinoni; Steven A Rosenberg; Richard M Siegel; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

Review 5.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

6.  Differentiation-dependent functional and epigenetic landscapes for cytokine genes in virus-specific CD8+ T cells.

Authors:  Alice E Denton; Brendan E Russ; Peter C Doherty; Sudha Rao; Stephen J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

7.  Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiation.

Authors:  Brendan E Russ; Moshe Olshanksy; Heather S Smallwood; Jasmine Li; Alice E Denton; Julia E Prier; Angus T Stock; Hayley A Croom; Jolie G Cullen; Michelle L T Nguyen; Stephanie Rowe; Matthew R Olson; David B Finkelstein; Anne Kelso; Paul G Thomas; Terry P Speed; Sudha Rao; Stephen J Turner
Journal:  Immunity       Date:  2014-11-06       Impact factor: 31.745

8.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

9.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  28 in total

Review 1.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  CAR T and CAR NK cells in multiple myeloma: Expanding the targets.

Authors:  Urvi A Shah; Sham Mailankody
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-13       Impact factor: 3.020

3.  Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Authors:  Matthew B Dong; Guangchuan Wang; Ryan D Chow; Lupeng Ye; Lvyun Zhu; Xiaoyun Dai; Jonathan J Park; Hyunu R Kim; Youssef Errami; Christopher D Guzman; Xiaoyu Zhou; Krista Y Chen; Paul A Renauer; Yaying Du; Johanna Shen; Stanley Z Lam; Jingjia J Zhou; Donald R Lannin; Roy S Herbst; Sidi Chen
Journal:  Cell       Date:  2019-08-22       Impact factor: 41.582

Review 4.  Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy.

Authors:  Caitlin C Zebley; Stephen Gottschalk; Ben Youngblood
Journal:  Trends Immunol       Date:  2020-07-02       Impact factor: 16.687

5.  De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.

Authors:  Hazem E Ghoneim; Yiping Fan; Ardiana Moustaki; Hossam A Abdelsamed; Pradyot Dash; Pranay Dogra; Robert Carter; Walid Awad; Geoff Neale; Paul G Thomas; Ben Youngblood
Journal:  Cell       Date:  2017-06-22       Impact factor: 41.582

6.  Droplet microfluidics for functional temporal analysis and cell recovery on demand using microvalves: application in immunotherapies for cancer.

Authors:  Sagar N Agnihotri; Giovanni Stefano Ugolini; Matthew Ryan Sullivan; Yichao Yang; Agustin De Ganzó; Ji Won Lim; Tania Konry
Journal:  Lab Chip       Date:  2022-08-23       Impact factor: 7.517

7.  LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.

Authors:  Eunsil Sung; Minkyung Ko; Ju-Young Won; Yunju Jo; Eunyoung Park; Hyunjoo Kim; Eunji Choi; Ui-Jung Jung; Jaehyoung Jeon; Youngkwang Kim; Hyejin Ahn; Da-Som Choi; Seunghyun Choi; Youngeun Hong; Hyeyoung Park; Hanbyul Lee; Yong-Gyu Son; Kyeongsu Park; Jonghwa Won; Soo Jin Oh; Seonmin Lee; Kyu-Pyo Kim; Changhoon Yoo; Hyun Kyu Song; Hyung-Seung Jin; Jaeho Jung; Yoon Park
Journal:  Mol Ther       Date:  2022-05-06       Impact factor: 12.910

8.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

9.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

10.  Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.

Authors:  Fengkun Lu; Lei Hou; Sizhen Wang; Yingjie Yu; Yunchang Zhang; Linhong Sun; Chen Wang; Zhiqiang Ma; Feng Yang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.